Macitentan 10 mg
Sponsors
Actelion, Janssen Research & Development, LLC
Conditions
Chronic Thromboembolic Pulmonary Hypertension (CTEPH)Congenital Heart DiseaseCongenital Heart Disease With Fontan CirculationDigital UlcersHealthyHeart Failure With Preserved Ejection Fraction and Pulmonary Vascular DiseasePulmonary Arterial HypertensionPulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
Phase 1
Study to Assess the Effect of Macitentan on the Electrocardiogram (ECG) in Healthy Male and Female Subjects
CompletedNCT02050802
Start: 2011-08-31End: 2011-11-30Updated: 2025-02-03
A Study of Macitentan/Tadalafil Combination Administered a Fixed-dose Combination Formulation Compared to the Reference Free Combination of Macitentan and Tadalafil
CompletedNCT04540744
Start: 2021-04-30End: 2021-08-30Updated: 2025-03-30
A Study of Fixed Dose Combination of Macitentan/Tadalafil (10 mg/20 mg) Compared to the Reference Free Combination of Macitentan and Tadalafil in Healthy Adult Participants
CompletedNCT05236231
Start: 2022-02-04End: 2022-05-14Updated: 2025-03-30
Phase 2
Phase 3
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
TerminatedNCT01474122
Start: 2011-12-31End: 2014-02-28Updated: 2025-02-04
Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome
CompletedNCT01743001
Start: 2013-05-21End: 2016-12-01Updated: 2018-02-23
Clinical Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Subjects
CompletedNCT03153137
Start: 2017-08-14End: 2021-07-26Updated: 2025-03-30
An Upcoming Clinical Study to Measure the Safety and Impact of a Drug Called Macitentan in Teenage and Adult Fontan Patients.
TerminatedNCT03775421
Start: 2019-04-11End: 2022-01-18Updated: 2023-03-07
A Clinical Study to Find Out if Macitentan is Effective and Safe in Japanese Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH).
TerminatedNCT03809650
Start: 2019-01-08End: 2020-06-29Updated: 2021-06-18
Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
CompletedNCT03904693
Start: 2019-07-29End: 2024-09-27Updated: 2025-12-19
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
Active, not recruitingNCT04273945
Start: 2020-06-30End: 2029-02-20Updated: 2026-03-13